Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Interference between effector RNAs expressed from conventional dual-function anti-HIV retroviral vectors can be circumvented using dual-effector-cassette retroviral vectors
Author: Peng, H.
Callison, D.
Li, P.
Burrell, C.
Citation: Human Gene Therapy, 1999; 10(3):449-462
Issue Date: 1999
ISSN: 1043-0342
Statement of
Hairong Peng, Deborah Callison, Peng Li, Christopher J. Burrell
Abstract: Coexpression of different effector molecules from a single vector (a dual-function vector) may provide enhanced efficacy. Thus far most of the reported anti-HIV dual-function vectors express different effector RNAs as a chimeric molecule. In our study involving retroviral vectors coexpressing a U5 ribozyme and either an anti-tat or anti-rev antisense RNA, chimeric vectors exhibit poor potency in several important functional aspects, including inhibition of HIV replication, protection against cytopathic effects, and suppression of target gene function. Surprisingly, such a poor efficacy of chimeric vector function was not associated with a lower level of effector RNA expression. These results indicate that expression of two effector RNAs as a chimeric molecule can lead to interference, reducing their global biological effects. More importantly, we have demonstrated that such interference can be avoided by coexpressing these effector RNAs as separate molecules through a new dual-function vector, called a dual-effector cassette (Dec) vector, developed in this study. We also define some of the design alterations that might affect the efficacy of the Dec vector and demonstrate that forward-designed Dec vectors are more efficacious than reverse-designed Dec vectors, which express a lower level of effector RNA owing to the instability of the 5' effector cassettes in the provirus. We believe that the principle of Dec vector design may also be applicable for the coexpression of other therapeutic RNA effectors in many gene therapy applications.
Keywords: Cell Line
Jurkat Cells
RNA, Catalytic
HIV Core Protein p24
Gene Products, tat
Transduction, Genetic
Reverse Transcriptase Polymerase Chain Reaction
Genetic Vectors
Models, Biological
Time Factors
tat Gene Products, Human Immunodeficiency Virus
Genetic Therapy
Rights: Copyright© Mary Ann Liebert, Inc. publishers. All rights reserved, USA and worldwide
DOI: 10.1089/10430349950018896
Appears in Collections:Aurora harvest 7
Microbiology and Immunology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.